IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Michela Bettati et al.

Serial No.:

To Be Assigned

Case No.: T1630P

US Nat'l Filing Date:

January 30, 2006

Int'l Appl'n No.

PCT/GB2004/003277

Int'l Filing Date:

July 29, 2004

For:

NOVEL GAMMA-SECRETASE INHIBITORS

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT EXPRESS MAIL NO.

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed

Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450

MAILED BY

Int'l Appl'n No.: Case No.: PCT/GB2004/003277

Case N Page T1630P

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

References A-C were listed in the International Search Report during the International Phase of this application. Also enclosed are copies of the International Search Report and Written Opinion of the International Searching Authority for this application.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

John C. Todaro, Reg. No. 36,036 Attorney for Applicant

MERCK & CO., Inc. P.O. Box 2000 Rahway, New Jersey 07065-0907 (732) 594-0125

Date: January 30, 2006

Sı	ubstitute for form 1449A/PTO			COMPLETE F KNOWN		
INFORMATION DISCLOSURE				Application Number	To Be Assigned 2 00 4 8 0	
	TATEMENT DV	AD	PDI ICANT	Filing Date	January 30, 2006	
STATEMENT BY APPLICANT				First Named Inventor	Michela Bettati et al.	
	(Group Art Unit	To Be Assigned	
	(use as many sheets	asr	iecessary)	Examiner Name	To Be Assigned	
Sheet	1	of	1	Attorney Docket Number	T1630P	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Docum	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Office Number Kind Code (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	A		WO 02/36555		Merck Sharp & Dohme Limited	05/10/2002
	В		WO 01/70677		Merck Sharp & Dohme Limited	09/27/2001
	С		WO 03/093251		Merck Sharp & Dohme Limited	11/13/2003

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.